 Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 4 | 1 | 5 | | 1999 | 3 | 0 | 3 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 3 | 4 | | 2002 | 3 | 1 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 4 | 5 | | 2006 | 2 | 1 | 3 | | 2007 | 1 | 2 | 3 | | 2008 | 7 | 1 | 8 | | 2009 | 8 | 3 | 11 | | 2010 | 5 | 2 | 7 | | 2011 | 3 | 6 | 9 | | 2012 | 4 | 3 | 7 | | 2013 | 12 | 0 | 12 | | 2014 | 8 | 7 | 15 | | 2015 | 12 | 11 | 23 | | 2016 | 19 | 9 | 28 | | 2017 | 10 | 7 | 17 | | 2018 | 13 | 11 | 24 | | 2019 | 7 | 10 | 17 | | 2020 | 22 | 13 | 35 | | 2021 | 6 | 13 | 19 | | 2022 | 3 | 10 | 13 | | 2023 | 3 | 7 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Denorme F, Armstrong ND, Stoller ML, Portier I, Tugolukova EA, Tanner RM, Montenont E, Bhatlekar S, Cody M, Rustad JL, Ajanel A, Tolley ND, Murray DC, Boyle JL, Nieman MT, McKenzie SE, Yost CC, Lange LA, Cushman M, Irvin MR, Bray PF, Campbell RA. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. J Clin Invest. 2023 09 15; 133(18).
-
Aijaz B, Glorioso TJ, Butala N, Waldo SW. Temporal trends and hospital variation in the use of P2Y12 inhibitors among patients undergoing percutaneous coronary intervention: Insights from the VA CART program. Catheter Cardiovasc Interv. 2023 09; 102(3):503-504.
-
Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 07 18; 12(14):e029588.
-
Brioso XB, Bolt M, Sammel MD, McKenney K. Abnormal uterine bleeding in anticoagulated patients by drug class: outcomes and management. Am J Obstet Gynecol. 2023 09; 229(3):318.e1-318.e14.
-
Bounajem MT, Joyce E, Scoville JP, Seinfeld J, Hoffman J, Grossberg JA, Waiters V, White AC, Nerva J, Burkhardt JK, Tonetti DA, El Naamani K, Gooch MR, Jabbour P, Tjoumakaris S, Ortega Gutierrez S, Levitt MR, Lang M, Ares WJ, Desai S, Mascitelli JR, Kilburg CJ, Budohoski KP, Couldwell WT, Gross BA, Grandhi R. Safety and efficacy of the Pipeline Flex embolization device with Shield Technology for the acute treatment of ruptured internal carotid artery pseudoaneurysms: a multi-institution case series. Neurosurg Focus. 2023 05; 54(5):E4.
-
Weissler EH, Stebbins A, Wruck L, Mu?oz D, Gupta K, Girotra S, Whittle J, Benziger CP, Polonsky TS, Bradley SM, Hammill BG, Merritt JG, Zemon DN, Hernandez AF, Jones WS. Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. Vasc Med. 2023 04; 28(2):122-130.
-
Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F, Diserafino L, Franzone A, Stabile E, Piccolo R, Cirillo P, Valgimigli M, Esposito G. Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry. EuroIntervention. 2023 03 20; 18(15):1266-1268.
-
Nay I, Hutchinson D, Rondina M, Kim K, Kroencke R, Kirkham A, Trujillo T, Tolley ND, Munger M. Prospective, randomized, controlled, trial to assess ASA DOSing by body mass index in HEalthy volunteers (DOSE study). Pharmacotherapy. 2023 03; 43(3):215-225.
-
Hess CN, Bonaca MP. Guideline-Directed Medical Therapy in?PAD: Time to Step on the Gas. JACC Cardiovasc Interv. 2023 02 13; 16(3):344-346.
-
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascul Pharmacol. 2023 04; 149:107145.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|